Ratio Therapeutics

Executive Summary

Ratio Therapeutics is a Boston-based biotech company pioneering a novel drug discovery and delivery platform called Trillium, which integrates proprietary radiopharmaceuticals with targeted delivery systems. The platform is designed to develop precision radiopharmaceuticals for oncology, aiming to improve therapeutic efficacy and reduce side effects. Founded in 2022, the company has raised $50 million to advance its pipeline of targeted alpha and beta particle therapies. Ratio's technology addresses key challenges in radiopharmaceuticals, such as tumor targeting and off-target toxicity, by leveraging a modular platform that enables rapid development of new candidates. With the growing interest in radiopharmaceuticals as a powerful modality for cancer treatment, Ratio is well-positioned to capitalize on this trend, though it remains at an early, platform stage without disclosed pipeline candidates. As a private company, its progress will be closely watched by investors seeking exposure to the next wave of targeted radiotherapies.

Upcoming Catalysts (preview)

• Q2 2026Lead candidate nomination for Trillium platform70% success
• H2 2026Partnership or collaboration with major pharma for radiopharmaceutical development60% success
• TBDIND submission for a lead candidate50% success